Enrollment Resumes in Masitinib Trials at Some European Sites

Enrollment Resumes in Masitinib Trials at Some European Sites

306662

Enrollment Resumes in Masitinib Trials at Some European Sites

A French national agency has cleared AB Science to resume patient enrollment in the Phase 3 clinical trial investigating masitinib in people with amyotrophic lateral sclerosis (ALS), the company announced in a press release. AB had voluntarily suspended recruitment and treatment in all its masitinib clinical studies in early June, after data suggested that the medication conferred a potential risk of ischemic heart disease, a condition characterized by recurring chest pain or discomfort. The go-ahead to resume enrollment…

You must be logged in to read/download the full post.